aIncreasing IUS discontinuation rates by 10%

Duration of useLARC methodTotal pregnanciesTotal costs (£)
1 yearIUD18195,442
IUS19274,397
2 yearsIUD57337,093
IUS63347,316
3 yearsIUD105337,207
IUS119436,935
4 yearsIUD166432,018
IUS183536,158
5 yearsIUD232534,555
IUS251640,237
6 yearsIUD299636,652
IUS319804,427
7 yearsIUD365736,023
IUS385904,801
8 yearsIUD429832,635
IUS4491,002,406
9 yearsIUD491958,830
IUS5121,097,299
10 yearsIUD5511,050,425
IUS5731,189,547
11 yearsIUD6101,139,234
IUS6321,327,438
12 yearsIUD6671,225,501
IUS6891,414,683
13 yearsIUD7221,309,296
IUS7451,499,483
14 yearsIUD7761,390,690
IUS7991,581,869
15 yearsIUD8281,469,754
IUS8521,661,917

As shown in the table, IUD dominates IUS (i.e. it is more effective and less costly) across all time periods examined.

From: Appendix D, Results of the sensitivity analysis

Cover of Long-acting Reversible Contraception
Long-acting Reversible Contraception: The Effective and Appropriate Use of Long-Acting Reversible Contraception.
NICE Clinical Guidelines, No. 30.
National Collaborating Centre for Women’s and Children’s Health (UK).
London: RCOG Press; 2005 Oct.
Copyright © 2005, National Collaborating Centre for Women’s and Children’s Health.

No part of this publication may be reproduced, stored or transmitted in any form or by any means, without the prior written permission of the publisher or, in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK [www.cla.co.uk]. Enquiries concerning reproduction outside the terms stated here should be sent to the publisher at the UK address printed on this page.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant laws and regulations and therefore for general use.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.